Overview of the Meeting and Biomarkers Workshop

The Meeting and Biomarkers Workshop is a focused educational event designed to accelerate progress in immunotherapy through the strategic use of biomarkers. Bringing together leading researchers, clinicians, and translational scientists, the workshop offers a platform to explore current challenges and emerging solutions in biomarker discovery, validation, and clinical implementation.

As immunotherapy continues to reshape the treatment landscape, biomarkers have become essential tools for patient selection, response monitoring, and toxicity management. This workshop aims to align scientific innovation with clinical practice, supporting more precise and effective therapeutic strategies.

Key Dates and Registration Details

Early Registration Discounts

Participants are encouraged to take advantage of early registration discounts available until September 12. Early registration not only offers cost savings but also helps secure access to popular sessions and interactive components of the program.

Abstract Submission Deadline

Researchers wishing to present their work during the Meeting and Biomarkers Workshop must submit their abstracts by July 20, 2009. Abstract submissions are welcomed from a broad range of disciplines, including basic science, translational research, clinical trials, and bioinformatics, provided they focus on biomarkers relevant to immunotherapy.

Accepted abstracts will be featured in dedicated sessions that foster discussion, critique, and collaboration, allowing investigators to refine their hypotheses and build new partnerships.

Scientific Focus: Biomarkers in Immunotherapy

Defining and Validating Biomarkers

The workshop will delve into the definition and categorization of biomarkers, covering predictive, prognostic, pharmacodynamic, and surrogate endpoints. Special attention will be given to analytical validation, clinical qualification, and the regulatory considerations that influence how biomarkers are integrated into trial design and clinical decision-making.

Translational Applications

Sessions will highlight practical approaches to moving biomarker discoveries from bench to bedside. Case studies will demonstrate how molecular signatures, immune cell phenotyping, and functional assays can inform patient stratification and treatment optimization in real-world clinical settings.

SITC Representation at the NHLBI-PACT Meeting

In recognition of the Society for Immunotherapy of Cancer (SITC) and its expertise in adoptive immunotherapy, several SITC members were invited to participate in the organizing efforts of the NHLBI-PACT (National Heart, Lung, and Blood Institute – Production Assistance for Cellular Therapies) Meeting. Their involvement underscores the critical role of coordinated, multi-institutional efforts in advancing cell-based therapies.

The NHLBI-PACT initiative supports the development, manufacturing, and testing of cellular therapies, and SITC’s participation strengthens the connection between cutting-edge immunotherapy research and the infrastructure required to bring these therapies to patients. Insights gained from that collaboration directly inform the agenda and strategic priorities of the Meeting and Biomarkers Workshop, particularly around standardizing assays and harmonizing biomarker methodologies.

Adoptive Immunotherapy and the Central Role of Biomarkers

Adoptive immunotherapy, including T-cell and NK-cell–based approaches, relies heavily on precise biomarkers to guide development and clinical use. Biomarkers can help identify optimal cell products, predict efficacy, monitor persistence and expansion in vivo, and detect early signs of toxicity.

The workshop will emphasize:

  • Biomarker-guided trial design to improve success rates of adoptive cell therapy studies.
  • Standardized immune monitoring for comparing results across trials and institutions.
  • Integration of omics technologies to uncover novel biomarkers and composite signatures.
  • Data sharing and harmonization as a foundation for robust biomarker validation.

Educational Value for Participants

Who Should Attend

The Meeting and Biomarkers Workshop is tailored for clinicians, laboratory scientists, trial designers, statisticians, and industry professionals who are involved in, or transitioning into, immunotherapy and biomarker-driven research. Early-career investigators, in particular, will benefit from exposure to both foundational concepts and evolving best practices.

Skills and Insights Gained

Attendees can expect to deepen their understanding of how to integrate biomarkers into the entire lifecycle of therapy development, from preclinical studies to late-phase clinical trials. By the conclusion of the workshop, participants will be better prepared to design biomarker strategies, interpret complex datasets, and engage in multidisciplinary collaborations that drive innovation.

Workshops, Case Studies, and Interactive Sessions

The program will feature a combination of expert lectures, panel discussions, and interactive breakout sessions. Real-world case studies will present both successes and challenges, illustrating how biomarker hypotheses are tested, refined, or refuted in practice.

Hands-on components may include guided discussions on assay selection, sample handling, and data integration. These elements are intended to provide practical takeaways that participants can apply immediately within their own institutions.

Positioning Within the Education and Workshops Program

This Meeting and Biomarkers Workshop forms a key part of a broader educational initiative focused on emerging topics in immunotherapy. Within the education and workshops framework, it serves as a nexus where scientific rigor, clinical acumen, and regulatory awareness intersect. The event not only updates participants on current trends but also helps shape consensus on future directions in biomarker-driven immunotherapy research.